The effectiveness of cytoprotection in the treatment of stable angina in patients with arterial hypertension and hyperuricemia, taking into account the peculiarities of the course of coronary artery disease in wartime

Victoriia Iablonska, L. Kholopov, O. Khyzhnyak, Viktoriia Batashova-Halinska
{"title":"The effectiveness of cytoprotection in the treatment of stable angina in patients with arterial hypertension and hyperuricemia, taking into account the peculiarities of the course of coronary artery disease in wartime","authors":"Victoriia Iablonska, L. Kholopov, O. Khyzhnyak, Viktoriia Batashova-Halinska","doi":"10.15587/2519-4798.2022.268523","DOIUrl":null,"url":null,"abstract":"The aim of the study is to establish the effectiveness of treatment of severe angina pectoris in patients with hyperuricemia, taking into consideration the peculiarities of the course of coronary artery disease (CAD) in wartime, using ranolazine – a selective inhibitor of the late sodium flow in combined pharmacotherapy. \nMaterials and methods. We studied the anti-anginal effect of ranolazine in 14 patients with CAD, stable angina pectoris III-IV functional class (FC), hyperuricemia and arterial hypertension (AH) during 6 months of the 2022 year. The effectiveness of the study drug on the clinical course of angina pectoris was assessed by questionnaire and clinical examination after three months of treatment. \nThe results. At the end of the second week of ranolazine use, angina attacks at rest, which were registered before the start of the observation, stopped in all patients with angina pectoris III FC and 50 % with angina pectoris IV FC. In 78.6 %, the number of angina attacks and the use of nitrates decreased by more than 2 times; 21.4 % no longer had angina attacks. \nAt the end of the first month, anginal attacks were not observed in all patients with angina pectoris III FC and 50 % with angina pectoris FC IV. In 2 patients with angina pectoris IV FC (50 %), anginal attacks continued to be registered during physical exertion and emotional stress, but no more than once a week. At the same time, there were no angina attacks at rest. The same results were obtained during the survey of patients at the end of three months of observation. \nConclusions. Ranolazine is an effective component of anti-anginal therapy, significantly affecting the patient's quality of life. Therefore, we can recommend ranolazine for patients with hyperuricemia in angina attacks that persist with insufficient effectiveness of zasic therapy with first-line drugs, especially during military conflicts","PeriodicalId":21672,"journal":{"name":"ScienceRise: Medical Science","volume":"66 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ScienceRise: Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15587/2519-4798.2022.268523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of the study is to establish the effectiveness of treatment of severe angina pectoris in patients with hyperuricemia, taking into consideration the peculiarities of the course of coronary artery disease (CAD) in wartime, using ranolazine – a selective inhibitor of the late sodium flow in combined pharmacotherapy. Materials and methods. We studied the anti-anginal effect of ranolazine in 14 patients with CAD, stable angina pectoris III-IV functional class (FC), hyperuricemia and arterial hypertension (AH) during 6 months of the 2022 year. The effectiveness of the study drug on the clinical course of angina pectoris was assessed by questionnaire and clinical examination after three months of treatment. The results. At the end of the second week of ranolazine use, angina attacks at rest, which were registered before the start of the observation, stopped in all patients with angina pectoris III FC and 50 % with angina pectoris IV FC. In 78.6 %, the number of angina attacks and the use of nitrates decreased by more than 2 times; 21.4 % no longer had angina attacks. At the end of the first month, anginal attacks were not observed in all patients with angina pectoris III FC and 50 % with angina pectoris FC IV. In 2 patients with angina pectoris IV FC (50 %), anginal attacks continued to be registered during physical exertion and emotional stress, but no more than once a week. At the same time, there were no angina attacks at rest. The same results were obtained during the survey of patients at the end of three months of observation. Conclusions. Ranolazine is an effective component of anti-anginal therapy, significantly affecting the patient's quality of life. Therefore, we can recommend ranolazine for patients with hyperuricemia in angina attacks that persist with insufficient effectiveness of zasic therapy with first-line drugs, especially during military conflicts
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
考虑到战时冠状动脉疾病病程的特殊性,细胞保护在治疗动脉高血压和高尿酸血症患者的稳定性心绞痛中的有效性
考虑到战时冠状动脉疾病(CAD)病程的特殊性,本研究的目的是确定在联合药物治疗中使用雷诺嗪(一种选择性晚期钠流抑制剂)治疗高尿酸血症患者的严重心绞痛的有效性。材料和方法。我们研究了雷诺嗪在2022年6个月期间对14例冠心病、稳定性心绞痛III-IV功能级(FC)、高尿酸血症和动脉高血压(AH)患者的抗心绞痛作用。治疗3个月后,通过问卷调查和临床检查评估研究药物对心绞痛临床病程的疗效。结果。在使用雷诺嗪的第二周结束时,所有III型FC心绞痛患者和50%的IV型FC心绞痛患者在静息时心绞痛发作(在观察开始前记录)停止。78.6%的患者心绞痛发作次数和硝酸盐用量下降2倍以上;21.4%不再有心绞痛发作。在第一个月结束时,所有III型心绞痛患者和50%的FC型心绞痛患者均未观察到心绞痛发作。在2例IV型心绞痛患者(50%)中,在体力消耗和情绪紧张期间仍记录到心绞痛发作,但不超过每周一次。同时,休息时没有心绞痛发作。在三个月的观察结束时,对患者的调查也得到了相同的结果。结论。雷诺嗪是抗心绞痛治疗的有效成分,显著影响患者的生活质量。因此,我们可以推荐雷诺嗪用于一线药物治疗效果不足的心绞痛发作的高尿酸血症患者,特别是在军事冲突期间
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
47
审稿时长
6 weeks
期刊最新文献
Analysis of exhaled breath condensate in patients with asthma and recurrent wheezing Sacrococcygeal pilonidal cyst with the disease onset as an anterior perianal abscess: a clinical case Body mass index, lipid profile, and endothelial dysfunction gene polymorphism in women with early-onset and late-onset preeclampsia Assessment of the implantation window and embryonic factor impact to the treatment of recurrent implantation failure (RIF). A prospective study Improvement of the methods of stopping nose bleeds in patients under antithrombotic therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1